Metformin Use in Kidney Transplant Recipients in the United States: An Observational Study

American Journal of Nephrology

Volumn 40, Issue 6, 2015, Pages 546-553

  Stephen, Jenise ^a   Anderson Haag, Teresa L ^a   Gustafson, Sally ^a   Snyder, Jon J ^a,b   Kasiske, Bertram L ^a,c   Israni, Ajay K ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allograft survival; Diabetes; Kidney transplant; Metformin; Patient survival

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; METFORMIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL; UNITED STATES; YOUNG ADULT; ADOLESCENT; BLOOD; EPIDEMIOLOGY; HEALTH INSURANCE; REGISTER; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; AGED; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, PHARMACEUTICAL SERVICES; KIDNEY TRANSPLANTATION; MALE; METFORMIN; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84923615010     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000370034     Document Type: Article

References (25)

1. US Renal Data System: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
2. Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW, Bunnapradist S: Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82: 1673-1676.
3. Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC: Can new-onset diabetes after kidney transplant be prevented Diabetes Care 2013; 36: 1406-1412.
4. Bristol-Myers Squibb Company: Glucophage (metformin hydrochlorine) Tablets (package insert). Princeton, NJ, USA, 2009.
5. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, Graham GG, Williams KM, Day RO: Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012; 14: 963-965.
6. Vasisht KP, Chen SC, Peng Y, Bakris GL: Limitations of metformin use in patients with kidney disease: are they warranted Diabetes Obes Metab 2010; 12: 1079-1083.
7. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P: Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
8. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G: Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci 2013; 17(suppl 1):45-49.
9. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB: Metformin and lactic acidosis: cause or coincidence A review of case reports. J Intern Med 2004; 255: 179-187.
10. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and metaanalysis. Arch Intern Med 2003; 163: 2594-2602.
11. Kajbaf F, Arnouts P, de Broe M, Lalau JD: Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf 2013; 22: 1027-1035.
12. Lipska KJ, Bailey CJ, Inzucchi SE: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
15. Sharif A: Should metformin be our antiglycemic agent of choice post-transplantation Am J Transplant 2011; 11: 1376-1381.
16. Leppke S, Leighton T, Zaun D, Chen SC, Skeans M, Israni AK, Snyder JJ, Kasiske BL: Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando) 2013; 27: 50-56.
17. Lexi-Comp: Lexi-Drugs Online 2014. http:// www.lexi.com/ (accessed November 6, 2014).
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
19. Executive summary: standards of medical care in diabetes-2013. Diabetes Care 2013; 36(suppl 1):S4-S10.
20. Stang M, Wysowski DK, Butler-Jones D: Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-927.
21. Bailey CJ, Nattrass M: Treatment-metformin. Baillieres Clin Endocrinol Metab 1988; 2: 455-476.
22. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG: Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094-1102.
23. Kurian B, Joshi R, Helmuth A: Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008; 14: 979-984.
24. Salvadori M, Bertoni E, Rosati A, Zanazzi M: Post-transplant diabetes mellitus. J Nephrol 2003; 16: 626-634.
25. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.